OraSure Technologies, Inc. (OSUR) Stake Lifted by Barclays PLC

Barclays PLC lifted its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 139.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 38,014 shares of the medical instruments supplier’s stock after purchasing an additional 22,171 shares during the period. Barclays PLC owned about 0.06% of OraSure Technologies worth $641,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Rhumbline Advisers grew its holdings in shares of OraSure Technologies by 2.8% in the first quarter. Rhumbline Advisers now owns 135,581 shares of the medical instruments supplier’s stock worth $2,290,000 after purchasing an additional 3,678 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of OraSure Technologies by 19.0% in the first quarter. Alps Advisors Inc. now owns 25,849 shares of the medical instruments supplier’s stock worth $437,000 after purchasing an additional 4,129 shares during the last quarter. Northern Trust Corp grew its holdings in shares of OraSure Technologies by 0.6% in the first quarter. Northern Trust Corp now owns 757,400 shares of the medical instruments supplier’s stock worth $12,792,000 after purchasing an additional 4,514 shares during the last quarter. Swiss National Bank grew its holdings in shares of OraSure Technologies by 4.9% in the fourth quarter. Swiss National Bank now owns 101,300 shares of the medical instruments supplier’s stock worth $1,911,000 after purchasing an additional 4,700 shares during the last quarter. Finally, ETRADE Capital Management LLC grew its holdings in shares of OraSure Technologies by 43.4% in the fourth quarter. ETRADE Capital Management LLC now owns 18,402 shares of the medical instruments supplier’s stock worth $347,000 after purchasing an additional 5,566 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating and set a $17.00 target price on the stock in a report on Wednesday, May 2nd. TheStreet cut shares of OraSure Technologies from a “b” rating to a “c+” rating in a report on Wednesday, May 2nd. BidaskClub cut shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 28th. Finally, ValuEngine cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Friday, May 4th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $20.75.

Shares of OSUR stock opened at $16.83 on Friday. OraSure Technologies, Inc. has a 52 week low of $12.86 and a 52 week high of $23.01. The firm has a market capitalization of $1.06 billion, a P/E ratio of 33.00, a price-to-earnings-growth ratio of 4.33 and a beta of 1.68.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. OraSure Technologies had a return on equity of 6.58% and a net margin of 9.28%. The company had revenue of $41.99 million during the quarter, compared to analyst estimates of $40.53 million. During the same quarter last year, the firm posted $0.21 earnings per share. The firm’s revenue was up 29.0% on a year-over-year basis. analysts expect that OraSure Technologies, Inc. will post 0.32 EPS for the current fiscal year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply